Aside from their suitability for automated screening, liquid-based Pap tests alone, when compared with smears, were shown to increase the sensitivity of the Pap test in the detection of epithelial cell abnormalities. Thus, in 1996, the US Food and Drug Administration (FDA) approved the first liquid-based Pap test, the ThinPrep, as a replacement for the smear. 1,2 In 1999, another liquid-based Pap test, the SurePath, formerly known as AutoCyte PREP, was also approved as a replacement for the smear. 3 In the United States, the majority of Pap tests are performed using liquid-based methods rather than the smear.
The MonoPrep Pap Test (MPPT; MonoGen, Lincolnshire, IL) is a novel, liquid-based specimen collection and processing technology for cytologic and molecular testing. Its usefulness in the detection of cervical cancer and its precursors was evaluated in
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In March 2006, the FDA approved the most recent liquidbased preparation, the MonoPrep Pap Test (MPPT). This report summarizes some of the results of a multicenter, masked, adjudicated, split-sample study performed to test the effectiveness of the MPPT. In this report (part I), the accuracy of the MonoPrep is compared with that of a conventional smear as adjudicated by a reference pathologist. Part II will review its accuracy based on histologic correlation, and Part III will summarize data on human papillomavirus (HPV) correlation.
Materials and Methods
The prospectively designed objective of this trial was to demonstrate that the MPPT provides a statistically significant improvement over screening with smears for the detection of independently confirmed epithelial abnormalities at 2 diagnostic thresholds: (1) atypical squamous cells of undetermined significance (ASC-US) and more severe lesions (ASC-US+) and (2) low-grade squamous intraepithelial lesion (LSIL) and more severe lesions (LSIL+). ASC-US cases were further stratified into "low-risk ASC-US" and "high-risk ASC-US" based on results of testing for HPV. A study protocol was developed, sample size estimates were made, and study design concepts were discussed with representatives of the Office of In Vitro Device Evaluation and Safety of the FDA; their suggestions were incorporated into the final study protocol and data analysis.
Women who underwent cervical Pap testing in the ordinary course of medical practice were eligible for inclusion in the study. Women without a cervix were excluded. Subjects had to be 18 years or older and able to provide written, informed consent. Informed consent was obtained from all subjects.
Samples were collected at sites in the United States (n = 75), South Africa (n = 11), and Venezuela (n = 2). Sites included family planning clinics, women's health care centers, hospital-based practices, colposcopy clinics, and physician practices specializing in obstetrics and gynecology, representing a spectrum of high-to low-prevalence populations with diverse ethnic and racial heritage, age, and geographic location. Institutional review board approval was obtained from all sites. Sample collection took place between March 1 and October 22, 2004.
All specimens were collected using the split-sample method. First, a smear was obtained and prepared using a plastic spatula and an endocervical cytobrush according to standard methods. 4 The residuum on the collection devices was then rinsed in an MPPT collection vial (MonoGen), the vial was closed, and the collection devices were discarded. A site coordinator completed a case report form (CRF) and a laboratory requisition form. Information captured on the CRF included the subject's demographic and gynecologic history (eg, date of birth; date of last menstrual period; race/ethnicity; previous Pap test and HPV results, if any; previous therapy or assessments for gynecologic malignancy; use of hormone products; and clinical observations of cervical condition at the time of collection). The collection site placed the MonoPrep vials and Pap smear slides in bags that were then shipped for examination.
The specimens and corresponding CRFs were first sent to a central laboratory (DCL Medical Laboratories, Indianapolis, IN) where they were checked for protocol compliance. Both Pap specimens were then forwarded to 1 of 4 study laboratories (CYTO Specialty Laboratories, San Antonio, TX; DCL Medical Laboratory, Indianapolis, IN; Pathology Services, Cambridge, MA; Universal Diagnostic Laboratories, Brooklyn, NY) for processing and assessment. Each of the 4 laboratories had experience in conventional and liquid-based Pap methods and an annual volume of at least 100,000 Pap cases. In nearly all cases, the matching Pap smear and MPPT specimen were sent to the same laboratory. Each laboratory had at least 2 study-designated screening cytotechnologists, at least 1 quality control (QC) cytotechnologist, at least 1 cytopathologist, and a study coordinator. All cytotechnologists were certified by the American Society for Clinical Pathology, and all cytopathologists were certified in anatomic pathology, with added qualification in cytopathology, by the American Board of Pathology. All cytotechnologists and cytopathologists also received training in MPPT morphology by means of a specially designed training module.
Random numbers were assigned to the cases and affixed to all MonoPrep vials, slides, and CRFs. CRFs and vials and slides were separated following accessioning such that subject names, initials, and other identifiers were not available or discernible to the cytotechnologists or cytopathologists. The codes that linked a smear to its pair-mate MonoPrep slide were not provided to the laboratory sites. Study personnel were instructed not to read MonoPrep and study-associated Pap smears on the same day. They were instructed not to compile average or comparative results, nor were they permitted to keep or refer to any personal or other log or notes of study-related Pap smears or MonoPrep slides that they, or any other person, had reviewed. All cytotechnologists and cytopathologists performed their reviews under such masked conditions. The study coordinator was not permitted to review slides at all.
The Pap smears were accessioned, racked, stained, and coverslipped in accordance with customary practice. 4 MonoPrep slides were prepared at the study laboratory using the MonoPrep Processor (MonoGen) ❚Image 1❚. The MonoPrep Processor is a fully automated batch-processing instrument capable of processing 40 samples per hour, with a throughput capacity of 324 samples per 8-hour run. An integrated stirrer mixed the specimen briefly to disperse mucus and aggregates. The specimen was then aspirated up into the hollow stirrer, and dual-flow technology captured a representative sample on a frit-backed filter (MonoGen). The MonoPrep filter was then pressed against the slide to transfer the cells onto a 20-mm-diameter circular area ❚Image 2❚. After cell transfer, the Processor applied a premeasured amount of reagent alcohol fixative directly onto the slide, which was allowed to dry. Slides were held in racks until stained. (They can be held up to 7 days at room temperature to 37°C without compromising specimen quality.) Pap smears were screened and interpreted by the study cytotechnologists and cytopathologists in the same manner as their routine practice. All slides were interpreted and results reported in accordance with the Bethesda System 2001 criteria and nomenclature. 5 Specifically, the Bethesda System 2001 criteria for liquid-based preparations were used to determine the adequacy of the MonoPrep preparations. As for all liquid-based preparations, a MonoPrep slide was required to have a minimum of 5,000 well-visualized and well-preserved squamous cells. Because the diameter of a MonoPrep cell deposition circle is the same as that for a ThinPrep, the guidelines for estimating cellularity were the same as those for the ThinPrep. 5 An endocervical/squamous metaplastic component was not required for adequacy, but its presence or absence was documented for all slides. For data analysis, all cases were classified into 1 of 9 general diagnostic categories: unsatisfactory; negative for an intraepithelial lesion or malignancy (NILM); NILM with reactive or reparative changes ( A screening cytotechnologist performed all first-pass interpretations of conventional and MonoPrep specimens. Pap smear slides were reviewed in the ordinary course of the cytologist's workload with other nonstudy slides, including other liquid-based Pap tests. On a given day, each cytotechnologist was assigned study-related smears or MonoPrep slides but not both. The slide allocation method was designed to ensure that, at the end of the study, each cytotechnologist had read approximately the same number of MonoPrep slides and study-related smears and that they were masked as to matching pairs. It was possible that a cytotechnologist would coincidentally read both slides in a pair by random allocation, but not on the same day, and only in a masked manner.
The designated QC cytotechnologist conducted a QC review of all cases designated as unsatisfactory by the screening cytotechnologist and at least 10% of all cases interpreted as NILM, including those from essentially all subjects meeting protocol-defined high-risk case criteria. At some laboratories, QC review of NILM and unsatisfactory slides was performed by the study cytopathologist. Cytotechnologists and cytopathologists completed the study CRFs as they evaluated each slide and had no further access to them.
The study coordinator at each laboratory oversaw daily activities of the study at that site. This person was responsible for maintaining the site notebook and ensuring prompt transmittal of CRF pages and resolution of data queries. All sites were independently monitored and audited.
If the MPPT or the smear slide from a case was interpreted as ASC-US or a more severe abnormality by the laboratory, both slides were submitted for masked review by an independent pathologist (IP). In addition, if the MPPT or the smear were interpreted as NILM-R, then, in virtually all (>98%) cases, both slides were reviewed by an IP. Approximately 6% of cases interpreted as NILM on both slides were submitted to an IP for a masked reference interpretation. In contrast with prior splitsample studies for liquid-based Pap tests, cases were not excluded from IP referral or performance analysis owing to a laboratory interpretation of unsatisfactory on one slide. The For essentially all (>98%) cases submitted for IP review, a test for HPV was performed using the hc2 HPV test (Digene, Gaithersburg, MD) using the high-risk (hr) probe set. The test was performed on 2 samples: a specimen co-collected (at the time the smear was obtained) with a Digene cervical sampler; and an aliquot from the MPPT specimen. HPV testing was performed for 2 reasons: (1) to query the relative sensitivities of the MPPT and smear for detection of hrHPV+ ASC-US, and (2) to validate the HPV assay on MPPT specimens. Results from this part of the study will be reported separately.
For each case reviewed by an IP, the reference diagnosis for the case was the most abnormal diagnosis from the 2 IPreviewed slides. Severity ranking was as follows: unsatisfactory < NILM < NILM-R < ASC-US (hrHPV-) < ASC-US (hrHPV+) < ASC-H < AGC < LSIL < HSIL < AIS < SCC < AC. The reference diagnosis was used as the cytologic "truth" diagnosis for the case and was termed the reference diagnosis by IP (RDIP). To assess the performance of the MPPT relative to the conventional Pap smear for each IP-reviewed case, the laboratory diagnoses made by the study sites using the 2 methods were compared with the RDIP. Data management was performed by HHI Clinical Research (Hunt Valley, MD). Completed CRF pages were transmitted by the laboratory site to the data management group via encrypted data fax, direct point-to-point fax, or by courier in batches. The data in the CRF were entered independently by 2 data entry personnel into a database. If their entries were identical, the entry was accepted into the data record; if there was a mismatch, the difference was resolved (eg, by examining the transcription or contacting the site for a CRF correction in case of illegibility). All data also received automated validity checks. Errors, ambiguity, or illegibility in the data resulted in immediate query by the project manager to the laboratory and/or collection site for prompt resolution.
Data listings and SAS tables (SAS Institute, Cary, NC) were prepared for statistical analysis. The ASC-US/SIL ratio was calculated by dividing the number of laboratory interpretations of ASC-US by the sum of LSIL + HSIL + AIS + SCC + AC interpretations. For analysis, the IP-established diagnosis was considered the subject's "true diagnosis" (= RDIP) for the calculation of true-positive and false-positive detection rates. This true diagnosis was the more severe of the 2 interpretations made by the IP for the subject's smear and MPPT slide pair-mate. Laboratory true-positive and false-positive detection rates for MPPTs and smears were calculated and the 95% confidence intervals (CIs) of their ratios evaluated for subjects with the RDIP equal to the following cutoffs: ASC-US+, ASC-H/AGC+, LSIL+, HSIL+, and cancer.
Among the cases at or above an RDIP cutoff (eg, LSIL+), a laboratory assessment for the MPPT or smear slide was considered a true-positive detection if the laboratory interpretation was at or above the RDIP cutoff (eg, laboratory assessment for RDIP = LSIL+ was LSIL, HSIL, or cancer). Conversely, the laboratory diagnosis for the smear or MPPT slide was considered a false-positive when the laboratory interpretation was greater than the RDIP for the subject (eg, a laboratory interpretation of HSIL was a false-positive if the MPPT and smear are interpreted as LSIL or lower by the IP). In determining true-positive and false-positive detection, the IP interpretation for a slide did not need to match the laboratory interpretation for the same slide. In other words, a laboratory detection of an abnormality was considered a true detection even when that abnormality was observed only on the other slide on IP review. The ratios of true-positive rates and ratios of false-positive rates and their 95% CIs were calculated for the cases with an RDIP of ASC-US+, ASC-H/AGC+, LSIL+, HSIL+, and cancer. 6 The statistical significance of ratios differing from 1.0 was demonstrated when the 95% CI did not include 1.00. 7, 8 The ability of each method to generate a satisfactory specimen was presented in a 2 × 2 table of satisfactory and unsatisfactory samples. A 2-sided McNemar test was conducted to examine differences in adequacy. For this analysis, subjects with unsatisfactory samples owing to collection site failure to provide documentary information were excluded from both arms. For the MonoPrep arm, a specimen was deemed unsatisfactory only if no satisfactory slide could be prepared from the specimen.
The number and percentage of infectious agents, benign conditions, and presence of a sufficient endocervical/transformation zone component (ECTZ) were summarized for the MonoPrep and Pap smear methods. Two-sided McNemar tests were used to examine rate differences between the methods.
Results
Paired specimens were obtained from 11,244 subjects, of which 339 were received after the study cutoff date and were not included in the analysis. Of the 10,905 accepted cases, 10,739 (98.5%) fulfilled eligibility criteria and were included in the statistical analysis. A summary of subject demographics is displayed in ❚Table 1❚. The mean age was 35.4 years (range, 18-90 years). A total of 3,500 (32.6%) subjects fulfilled criteria that placed them at high risk for developing cervical cancer; 509 (4.7%) were pregnant, and 1,402 (13.1%) were postmenopausal.
The laboratory interpretations for the 10,739 smear and MPPT pairs are displayed in ❚Table 2❚. The MPPT and smear interpretations were exactly concordant in 8,290 cases (77.2%). There are 1,404 cases in the lower left of Table 2 that represent cases with a more severe interpretation on the MPPT slide than on the smear pair-mate. This number is 34.4% greater than the 1,045 cases in the upper right, which represent cases with a more severe interpretation on the smear as compared with the MPPT. The ASC-US/SIL ratio was 1.77 for the smears and 1.51 for the MPPT (-15%). True-positive and false-positive ratios for the MPPT and smear interpretations at 5 diagnostic thresholds are shown in ❚Table 5❚. For the cases with an RDIP of ASC-US+, the MPPT method detected 1.15 (1,274/1,111) times more true-positive cases than the smear method for all sites combined. This increase is statistically significant. The observed ratios of the true-positive rates varied among the sites from 1.02 to 1.49. The ratio of the false-positive rates for ASC-US+ was 0.92 (271/296) for all sites combined (range, 0.55-1.51). The observed decrease in the false-positive MPPT rate relative to the false-positive smear rate is not statistically significant.
For cases with an RDIP of ASC-H/AGC+, the MPPT method detected 1.23 (537/438) times more true-positive cases than the smear method detected for all sites combined. This increase is statistically significant. The observed ratios of the true-positive rates varied among the sites from 1.11 to 1.67. The ratio of the false-positive rates for ASC-H/AGC+ was 0.95 (115/121) for all sites combined (range, 0.63-1.35). The observed decrease in the false-positive MPPT rate relative to the false-positive smear rate is not statistically significant. Diagnosis  UNSAT  NILM  NILM-R ASC-US  ASC-H  AGC  LSIL  HSIL  AIS  SCC  AC  Total   UNSAT  43  58  6  12  0  0  5  2  0  0  0  126  NILM  209  7,744  198  459  16  35  55  15  0  0  1  8,732  NILM-R  11  214  59  40  1  1  6  2  0  1  0  335  ASC-US  23  538  41  201  4  7 
For cases with an RDIP of LSIL+, the MPPT method detected 1.26 (486/385) times more true-positive cases than the smear method detected for all sites combined. This increase is statistically significant. The observed ratios of the positive rates varied among the sites from 1.14 to 1.53. The ratio of the false-positive rates for LSIL+ was 1.13 (107/95) for all sites combined (range, 0.71-1.56). The observed increase in the false-positive MPPT rate relative to the falsepositive smear rate is not statistically significant.
For cases with an RDIP of HSIL+, the MPPT method detected 1.04 (113/109) times more true-positive cases than the smear method detected for all sites combined. This increase is not statistically significant. The observed ratios of the true-positive rates varied among the sites from 0.96 to 1.33. The ratio of the false-positive rates for HSIL+ was 0.68 (21/31) for all sites combined (range, 0.40-1.33). The observed decrease in the false-positive MPPT rate relative to the false-positive smear rate is not statistically significant. For the 46 cases with an RDIP of cancer, the MPPT method detected 1.22 (28/23) times more true-positive cases than the smear method detected for all sites combined. This increase is not statistically significant and has a 95% CI of 0.87 to 1.70. The ratio of the false-positive rates for cancer was 0.67 (4/6) for all sites combined (range, 0.5-0.75). The observed decrease in the false-positive MPPT rate relative to the false-positive smear rate is not statistically significant.
❚Table 6❚ shows a comparison of specimen adequacy interpretations for the conventional smear and the MPPT methods for all sites combined. There were 302 interpretations of unsatisfactory on the smears and 126 (58% fewer) on the MPPT preparations. The unsatisfactory rate was significantly lower (P < .00001) for the MPPT (1.2%; range for all sites, 0.3-2.0%) than for the smear method (2.8%; range for all sites, 0.8-3.9).
Laboratories assessed slides for the presence of an adequate ECTZ. As shown in ❚Table 7❚, the ECTZ was absent or insufficient in 43 fewer MPPT than smear slides (-3.3%; 95% CI, -8.5% to 2.1%; P = .225), a difference that is not statistically significant. There were equivalent distributions in the number of MPPTs and smears with ECTZ considered "detectable" (1-10 cells), "typical" (11-25 cells), and "abundant" (>25 cells) (data not shown). Similar equivalence between the MPPT and smear was observed with the distributions between MPPT and smear in the quantity of abnormal cells (data not shown).
The MPPT vs smear interpretations showed no statistically significant difference in the detection of reactive or reparative conditions and infectious agents. ❚Table 8❚ shows the detection rates for these conditions and agents.
Discussion
In this study, the MonoPrep Pap test was evaluated by comparing its performance with that of the direct smear, and relative sensitivity and specificity were calculated based on an independent assessment of the slides by a reference pathologist. This method of test comparison was used in the evaluations of the ThinPrep and the SurePath Pap tests. 2, 9 This study has shown that slides prepared by the MPPT, as compared with smears, yield statistically significant increases in true-positive cytologic results, as judged by an IP, for the diagnostic thresholds ASC-US+, ASC-H/AGC+, and LSIL+. Increases at these thresholds were observed for all study laboratories. Based on independent reference review interpretations, disease detection with MPPT was significantly increased at all thresholds (ASC-US+, ASC-H/AGC+, LSIL+, HSIL+, and cancer). Comparisons of false-positive rates did not show a statistically significant difference between MPPT and smears at these (or any) diagnostic thresholds, confirming that the increase in relative sensitivity achieved with the MPPT reflected a true increase in diagnostic accuracy.
These results are arguably stronger than those obtained in the multicenter split-sample clinical trials of 7,360 ThinPrep Pap tests and 8,983 SurePath Pap tests. [1] [2] [3] 9 The data in those reports and in this one are not directly comparable because of different cohorts and a difference in the statistical analysis. Nevertheless, in the SurePath (formerly AutoCyte PREP) clinical trial, 3 the difference between smear and SurePath in the detection of epithelial lesions was not significant for ASC-US or LSIL+. In the ThinPrep clinical trial, the increase in detection was significant for ASC-US+ and LSIL+ only for a subset of trial sites. The inability to demonstrate a significant difference in the detection of HSIL+ in any of the 3 clinical trials likely represents the limitations of sample size. It may also reflect, in this study, the limitations of the study protocol, which defined truth as an RDIP based on the highest abnormality observed on either or both slides of a case. This formulation allows a laboratory overcall of HSIL to be tallied as a correct interpretation even when it is not confirmed for that slide by IP review (ie, the abnormality is correctly interpreted only on the other slide). If one examines the IP interpretations independently (Table 3 ) and accepts them as truth, then the MPPT shows a significant improvement over the smear at the thresholds of HSIL+ and cancer.
The method for assessing test accuracy in this study, which was based on review of the slides by an IP, met the approval of the FDA and was also used in the clinical trials for the approvals of the ThinPrep 2 and SurePath 9 Pap tests. Data using other accuracy assessment methods (correlation with HPV and biopsy results) were also obtained; those results will be published separately.
The MPPT is the first liquid-based Pap method approved by FDA since 1999. MPPT slides show the uniformity and the reduction of artifacts commonly associated with other liquidbased Pap tests. The MonoPrep Processor also incorporates several enhancements. It is a fully automated, batch-processing instrument with end-to-end bar-coding technology that ensures specimen integrity and chain of custody. It prevents cross-contamination by automated vial and waste handling, aerosol prevention, discrete slide fixation and dry slide storage, and automated vial resealing using plastic film. The MPPT system is an effective method for preparing gynecologic cytology slides to screen for cervical abnormalities and can serve as a replacement for the Pap smear.
